MiPLA Facts
Psychedelic;
Description
MiPLA (N-methyl-N-isopropyllysergamide) is a semi-synthetic psychedelic of the lysergamide class. It activates serotonin receptors, disrupting sensory filtering and producing the visual and cognitive shifts characteristic of classical psychedelics.
Subjective effects include euphoria, tactile enhancement, brightened colors, light surface patterning, and stimulation. The experience is body-forward — warm physical engagement with modest visuals and notably less cognitive weight than LSD, closer to a different balance of the same pharmacology than a diluted copy.
MiPLA produces no physical dependence, and no lethal dose has been established — rapid tolerance makes compulsive redosing self-limiting.[1] The primary risk is psychological: panic in uncontrolled settings, compounded by the possibility that blotters sold as LSD may contain MiPLA at different potency.[2]
Dose and durationby route · individual sensitivity varies
Starts in 20 – 40 minLasts 4 – 6 hoursAfter-effects 2 – 4 hours
Body and dependence
- Acute toxicity
- Negligible
- Chronic toxicity
- Low
- Physical dependence
- None
- Psychological dependence
- Low
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 14 days
- Carries over to
- LSD;
psilocybin; mescaline; DMT; 2C-B; DOI
Effectslikely at a common dose
- Perception
- Color enhancement;
Visual drifting; Color alteration; Music enhancement; Geometry; Visual breathing; +26 possible, including Spatial disorientation, Visual haze / noise, Vestibular distortion - Body
- Pupil dilation;
Wakefulness; Stimulation; Body scan awareness; Insomnia; +26 possible, including Muscle tension, Dizziness, Heart rate perception changes - Thinking
- Conceptual thinking;
Novelty enhancement; Pattern recognition enhancement; Aesthetic enhancement; Cognitive flexibility; Introspection enhancement; Openness enhancement; Thought connectivity; +24 possible, including Suggestibility enhancement, Thought loops, Memory suppression - Feeling
- Emotional enhancement;
+8 possible, including Emotional lability, Anxiety, Paranoia - Self
- Emotional susceptibility;
+9 possible, including Derealization, Depersonalization - Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 3 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [2]^Brandt SD, Kavanagh PV, Westphal F, Stratford A, Blanckaert P, Dowling G, Grill M, Schwelm HM, Auwärter V, Chapman SJ (2022) Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA — Drug Testing and Analysis doi:10.1002/dta.3103